Bank of Montreal Can Has $148.21 Million Position in Novo Nordisk A/S (NYSE:NVO)

Bank of Montreal Can boosted its position in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 53.7% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,722,937 shares of the company's stock after buying an additional 601,845 shares during the period. Bank of Montreal Can's holdings in Novo Nordisk A/S were worth $148,207,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of NVO. GQG Partners LLC lifted its position in shares of Novo Nordisk A/S by 74.7% during the 4th quarter. GQG Partners LLC now owns 12,994,533 shares of the company's stock worth $1,117,790,000 after buying an additional 5,556,460 shares during the last quarter. Loomis Sayles & Co. L P raised its stake in Novo Nordisk A/S by 34.2% during the fourth quarter. Loomis Sayles & Co. L P now owns 11,571,686 shares of the company's stock worth $995,397,000 after acquiring an additional 2,947,771 shares in the last quarter. Folketrygdfondet lifted its holdings in shares of Novo Nordisk A/S by 0.5% in the fourth quarter. Folketrygdfondet now owns 8,903,938 shares of the company's stock worth $765,917,000 after acquiring an additional 40,313 shares during the last quarter. Sustainable Growth Advisers LP boosted its stake in shares of Novo Nordisk A/S by 23.6% in the 4th quarter. Sustainable Growth Advisers LP now owns 5,340,803 shares of the company's stock valued at $459,416,000 after purchasing an additional 1,021,498 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new stake in shares of Novo Nordisk A/S during the fourth quarter worth $404,910,000. 11.54% of the stock is owned by institutional investors.

Remove Ads

Analysts Set New Price Targets

A number of brokerages have issued reports on NVO. Morgan Stanley assumed coverage on Novo Nordisk A/S in a report on Wednesday, February 12th. They issued an "equal weight" rating for the company. Sanford C. Bernstein raised Novo Nordisk A/S from an "underperform" rating to a "market perform" rating in a research note on Monday, January 6th. BMO Capital Markets cut their target price on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an "outperform" rating on the stock in a research report on Monday, December 23rd. Stifel Nicolaus cut shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research report on Monday, March 3rd. Finally, StockNews.com raised shares of Novo Nordisk A/S from a "buy" rating to a "strong-buy" rating in a research note on Monday. Three research analysts have rated the stock with a hold rating, six have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $145.25.

Novo Nordisk A/S Trading Up 5.2 %

Novo Nordisk A/S stock traded up $3.18 during mid-day trading on Friday, hitting $64.39. 6,564,023 shares of the stock were exchanged, compared to its average volume of 5,771,452. The stock has a market capitalization of $288.94 billion, a price-to-earnings ratio of 19.56, a PEG ratio of 0.90 and a beta of 0.61. Novo Nordisk A/S has a 12 month low of $59.32 and a 12 month high of $148.15. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62. The firm's fifty day simple moving average is $78.23 and its two-hundred day simple moving average is $93.98.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, topping analysts' consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. Analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The firm also recently announced a semi-annual dividend, which was paid on Tuesday, April 8th. Investors of record on Monday, March 31st were given a dividend of $0.7874 per share. This is a positive change from Novo Nordisk A/S's previous semi-annual dividend of $0.51. The ex-dividend date of this dividend was Monday, March 31st. This represents a dividend yield of 1.2%. Novo Nordisk A/S's dividend payout ratio is presently 49.54%.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.